#Japan #Tokyo #Crohn's Disease #AbbVie #Risankizumab

AbbVie Seeks New Therapy Route for Crohn's Disease Patients

AbbVie, based in Minato-ku, Tokyo, is making strides in the treatment of Crohn's disease with the recent submission of an application for a partial change in approval to introduce subcutaneous administration of Risankizumab for adult patients with moderate to severe active Crohn's disease. This initiative is based on the results of the international Phase 3 AFFIRM trial, which compared the efficacy and safety of subcutaneous Risankizumab against a placebo for induction therapy.

Understanding Crohn's Disease

Crohn's disease is a chronic inflammatory condition primarily affecting the gastrointestinal tract, causing symptoms such as diarrhea, abdominal pain, and rectal bleeding. Most commonly it manifests in teenagers and young adults, with an estimated 100,000 patients currently living with the disease in Japan, a number that is steadily increasing. The disease is progressive and tends to worsen over time, making it challenging for patients both physically and mentally. The unpredictability of symptoms can create significant emotional and financial stress, leading to frequent hospitalizations and surgery as the condition escalates.

The Need for Effective Therapies

The primary goals of Crohn's disease treatment focus not only on controlling disease activity but also on enhancing patients' quality of life and achieving long-term outcomes such as mucosal healing. Shared decision-making between patients and healthcare providers is crucial for improving prognosis. Currently, Risankizumab is approved only for intravenous administration as an induction therapy. This newly proposed subcutaneous option aims to provide greater convenience and reduced patient burden, thus enhancing the therapeutic landscape for Crohn's disease management.

The Science Behind Risankizumab

Risankizumab is an IL-23 inhibitor that blocks the p19 subunit of interleukin-23, a cytokine believed to play a pivotal role in the inflammatory processes associated with various chronic immune-mediated inflammatory diseases, including Crohn's disease. Developed in collaboration between AbbVie and Boehringer Ingelheim, AbbVie has taken the lead in the global development and commercialization of Risankizumab.

AbbVie's Commitment to Innovation

AbbVie's mission is to tackle severe health challenges by creating innovative medicines and providing solutions to meet unmet medical needs. The company's focus spans several areas including immune disorders, neuroscience, oncology, and aesthetic medicine through its Allergan Aesthetics portfolio. In Japan, AbbVie is actively working on developing and delivering products primarily in the fields of immune disorders, liver diseases, CNS diseases, oncology, and eye care.

Conclusion

The potential approval of Risankizumab for subcutaneous use in Crohn's disease represents a significant advancement in treatment options available to patients. As the landscape evolves, the hope is to alleviate the burden faced by patients and to support them in their journey towards better health outcomes. For more information on AbbVie, please visit www.abbvie.com or their regional site www.abbvie.co.jp.